BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 15293907)

  • 1. [Biofilm production and antifungal susceptibility patterns of Candida species].
    Yücesoy M; Karaman M
    Mikrobiyol Bul; 2004; 38(1-2):91-8. PubMed ID: 15293907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution and antifungal susceptibility of Candida species causing candidemia from 1996 to 1999.
    Cheng MF; Yu KW; Tang RB; Fan YH; Yang YL; Hsieh KS; Ho M; Lo HJ
    Diagn Microbiol Infect Dis; 2004 Jan; 48(1):33-7. PubMed ID: 14761719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CHROMAgar Candida with fluconazole: comparison with microdilution techniques].
    Linares MJ; Charriel G; Solís F; Casal M
    Enferm Infecc Microbiol Clin; 2003 Nov; 21(9):493-7. PubMed ID: 14572382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidemia in a tertiary care cancer center: in vitro susceptibility and its association with outcome of initial antifungal therapy.
    Antoniadou A; Torres HA; Lewis RE; Thornby J; Bodey GP; Tarrand JP; Han XY; Rolston KV; Safdar A; Raad II; Kontoyiannis DP
    Medicine (Baltimore); 2003 Sep; 82(5):309-21. PubMed ID: 14530780
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance.
    Krcmery V; Barnes AJ
    J Hosp Infect; 2002 Apr; 50(4):243-60. PubMed ID: 12014897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Determination of the in vitro antifungal susceptibility of clinically important yeasts using the Sensititre system].
    Carrillo-Muñoz AJ; Quindós G; Gasser I; Tur-Tur C; Ruesga MT; Alonso-Vargas R; Arévalo P; Bornay-Llinares FJ; Santos P; del Valle O
    Rev Esp Quimioter; 1999 Jun; 12(2):126-35. PubMed ID: 10562673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of clinical isolates of Candida lusitaniae to five systemic antifungal agents.
    Favel A; Michel-Nguyen A; Datry A; Challier S; Leclerc F; Chastin C; Fallague K; Regli P
    J Antimicrob Chemother; 2004 Mar; 53(3):526-9. PubMed ID: 14963064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of yeasts as nosocomial pathogens & their susceptibility to fluconazole & amphotericin B.
    Prasad KN; Agarwal J; Dixit AK; Tiwari DP; Dhole TN; Ayyagari A
    Indian J Med Res; 1999 Jul; 110():11-7. PubMed ID: 10709333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Multisite evaluation of a colorimetric broth microdilution antifungal susceptibility testing].
    Yamane N; Igari J
    Rinsho Byori; 1997 Feb; 45(2):190-9. PubMed ID: 9121005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro susceptibility of 115 isolates of Candida to amphotericin B, fluconazole and itraconazole.
    Mallié M; Bastide JM
    Drugs Exp Clin Res; 1996; 22(6):301-7. PubMed ID: 9034756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Studies on microtiter broth dilution method for antifungal susceptibility testing of yeast isolates from blood and cerebrospinal fluid].
    Fujita S
    Rinsho Byori; 1996 Apr; 44(4):373-8. PubMed ID: 8847821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Identification and antifungal susceptibility of Candida spp isolated from invasive mycoses. Influence of growth inhibition percentage to determine minimal inhibitory concentration].
    Alvarado D; Díaz MC; Silva V
    Rev Med Chil; 2002 Apr; 130(4):416-23. PubMed ID: 12090107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis.
    Yang YL; Ho YA; Cheng HH; Ho M; Lo HJ
    Infect Control Hosp Epidemiol; 2004 Jan; 25(1):60-4. PubMed ID: 14756222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The value of the agar dilution method as a screening test for determining the sensitivity of Candida albicans to fluconazole].
    Yücesoy M; Marol S
    Mikrobiyol Bul; 2002; 36(3-4):317-22. PubMed ID: 12838666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Architecture, influencing factors, and sensitivity to antifungal agents of Candida biofilm].
    Sun QN; Fang K
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Aug; 24(4):385-8. PubMed ID: 12905659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candidemia and the susceptibility pattern of Candida isolates in blood.
    Osoba AO; Al-Mowallad AW; McAlear DE; Hussein BA
    Saudi Med J; 2003 Oct; 24(10):1060-3. PubMed ID: 14578968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the susceptibility of yeast isolates of clinical interest to five antifungal agents using the E test.
    Linares MJ; Muñoz JF; Solís F; Rodríguez FC; Valero A; Casal M
    Rev Esp Quimioter; 1998 Mar; 11(1):64-9. PubMed ID: 9795292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Molecular epidemiologic surveillance and antifungal agent sensitivity of Candida albicans isolated from anesthesia intensive care units].
    Gülay Z; Ergon C; Ozkütük A; Yücesoy M; Biçmen M
    Mikrobiyol Bul; 2002; 36(3-4):309-16. PubMed ID: 12838665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Evaluation of Candida species' susceptibility to fluconazole with the disk diffusion method].
    de Bedout C; Ayabaca J; Vega R; Méndez M; Santiago AR; Pabón ML; Tabares A; Arango M; Restrepo A; Newell V
    Biomedica; 2003 Mar; 23(1):31-7. PubMed ID: 12696397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.